Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bruce M. Ewenstein, M.D.,Ph.D.

Title
Institution
Department
Address

Research
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. R01HL045629 (EWENSTEIN, BRUCE M) Jan 1, 1993 - Dec 31, 1997
    NIH
    THROMBIN-STIMULATED ENDOTHELIAL CELL SECRETION
    Role: Principal Investigator
  2. K08HL001657 (EWENSTEIN, BRUCE M) Dec 1, 1985 - Nov 30, 1990
    NIH
    BIOSYNTHESIS OF VON WILLEBRAND FACTOR BY ENDOTHELIUM
    Role: Principal Investigator

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Oladapo A, Wu Y, Lu M, Farahbakhshian S, Ewenstein B. Economic Burden Associated with Major Surgery in Patients with von Willebrand Disease: A United States Retrospective Administrative Database Analysis. J Blood Med. 2021; 12:699-708. PMID: 34393536; PMCID: PMC8357406.
    Citations:    
  2. Klamroth R, Windyga J, Radulescu V, Collins PW, Stasyshyn O, Ibrahim HM, Engl W, Tangada SD, Savage W, Ewenstein B. Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood. 2021 04 01; 137(13):1818-1827. PMID: 33150384; PMCID: PMC8039905.
    Citations: 8     Fields:    Translation:HumansCTClinical Trials
  3. Pabinger I, Mamonov V, Windyga J, Engl W, Doralt J, Tangada S, Spotts G, Ewenstein B. Results of a randomized phase III/IV trial comparing intermittent bolus versus continuous infusion of antihaemophilic factor (recombinant) in adults with severe or moderately severe haemophilia A undergoing major orthopaedic surgery. Haemophilia. 2021 May; 27(3):e331-e339. PMID: 33772963; PMCID: PMC8252548.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  4. Turecek PL, Peck RC, Rangarajan S, Reilly-Stitt C, Laffan MA, Kazmi R, James I, Dushianthan A, Schrenk G, Gritsch H, Ewenstein BM, Mellgard B, Erdlenbruch W, Jain N, Binder NB, Mumford AD. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19. Thromb Res. 2021 05; 201:100-112. PMID: 33662796; PMCID: PMC7890348.
    Citations: 20     Fields:    Translation:HumansCells
  5. Konkle BA, Walsh CE, Escobar MA, Josephson NC, Young G, von Drygalski A, McPhee SWJ, Samulski RJ, Bilic I, de la Rosa M, Reipert BM, Rottensteiner H, Scheiflinger F, Chapin JC, Ewenstein B, Monahan PE. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021 02 11; 137(6):763-774. PMID: 33067633; PMCID: PMC7885820.
    Citations: 29     Fields:    Translation:HumansCellsCTClinical Trials
  6. Lu M, Oladapo A, Wu Y, Farahbakhshian S, Ewenstein B. Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States. J Manag Care Spec Pharm. 2021 Feb; 27(2):175-185. PMID: 33307935.
    Citations: 1     Fields:    Translation:Humans
  7. Oladapo AO, Ito D, Hibbard C, Bean SE, Krupnick RN, Ewenstein BM. Patient Experience with Congenital (Hereditary) Thrombotic Thrombocytopenic Purpura: A Conceptual Framework of Symptoms and Impacts. Patient. 2019 10; 12(5):503-512. PMID: 31359341; PMCID: PMC6697707.
    Citations: 1     Fields:    Translation:Humans
  8. Turecek PL, Spannagl M, Kragh T, Allmaier G, Turecek M, Schrenk G, Gritsch H, Obermann-Slupetzky O, Ewenstein BM, Valentino LA. The role of ultralarge multimers in recombinant human von Willebrand factor - a review of physico-and biochemical studies and findings in in vivo models and in humans with von Willebrand disease. Hamostaseologie. 2017; 37(S 01):S15-S25. PMID: 29582921.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  9. Bykov K, Bohn RL, Ewenstein BM, Seeger JD, Avorn J, Bateman BT. Use of Bypassing Agents and Risk of Thromboembolic Events in Patients with Haemophilia and Inhibitors. Thromb Haemost. 2017 12; 117(12):2267-2273. PMID: 29212114.
    Citations: 1     Fields:    Translation:Humans
  10. Aledort LM, Ewenstein BM. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. N Engl J Med. 2017 11 30; 377(22):2193. PMID: 29188944.
    Citations: 1     Fields:    Translation:Humans
  11. Scully M, Hibbard C, Ewenstein B. Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura. Oncoscience. 2017 Nov; 4(11-12):160-161. PMID: 29344548; PMCID: PMC5769974.
    Citations: 3     
  12. Scully M, Knöbl P, Kentouche K, Rice L, Windyga J, Schneppenheim R, Kremer Hovinga JA, Kajiwara M, Fujimura Y, Maggiore C, Doralt J, Hibbard C, Martell L, Ewenstein B. Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood. 2017 11 09; 130(19):2055-2063. PMID: 28912376; PMCID: PMC5680611.
    Citations: 65     Fields:    Translation:HumansCTClinical Trials
  13. Valentino LA, Pipe SW, Collins PW, Blanchette VS, Berntorp E, Fischer K, Ewenstein BM, Oh M, Spotts G. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia. 2016 Jul; 22(4):514-20. PMID: 26930418.
    Citations: 19     Fields:    Translation:Humans
  14. Varadi K, Tangada S, Loeschberger M, Montsch P, Schrenk G, Ewenstein B, Turecek PL. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy. Haemophilia. 2016 Jul; 22(4):615-24. PMID: 26879158.
    Citations: 14     Fields:    Translation:Humans
  15. Carcao M, Re W, Ewenstein B. The role of previously untreated patient studies in understanding the development of FVIII inhibitors. Haemophilia. 2016 Jan; 22(1):22-31. PMID: 26315604.
    Citations: 7     Fields:    Translation:HumansAnimals
  16. Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FW, Obermann-Slupetzky O, Chapman M, Fritsch S, Pavlova BG, Presch I, Ewenstein B. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015 Oct 22; 126(17):2038-46. PMID: 26239086; PMCID: PMC4616237.
    Citations: 38     Fields:    Translation:HumansCTClinical Trials
  17. Konkle BA, Stasyshyn O, Chowdary P, Bevan DH, Mant T, Shima M, Engl W, Dyck-Jones J, Fuerlinger M, Patrone L, Ewenstein B, Abbuehl B. Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A. Blood. 2015 Aug 27; 126(9):1078-85. PMID: 26157075; PMCID: PMC4551361.
    Citations: 69     Fields:    Translation:HumansCTClinical Trials
  18. Kruse-Jarres R, St-Louis J, Greist A, Shapiro A, Smith H, Chowdary P, Drebes A, Gomperts E, Bourgeois C, Mo M, Novack A, Farin H, Ewenstein B. Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A. Haemophilia. 2015 Mar; 21(2):162-170. PMID: 25623166.
    Citations: 39     Fields:    Translation:HumansAnimalsCTClinical Trials
  19. Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015 Apr; 8(2):237-46. PMID: 25600578.
    Citations: 17     Fields:    Translation:Humans
  20. Berntorp E, Spotts G, Patrone L, Ewenstein BM. Advancing personalized care in hemophilia A: ten years' experience with an advanced category antihemophilic factor prepared using a plasma/albumin-free method. Biologics. 2014; 8:115-27. PMID: 24741292.
    Citations: 11     
  21. Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014 Jul; 20(4):459-63. PMID: 24472015.
    Citations: 24     Fields:    Translation:Humans
  22. Antunes SV, Tangada S, Stasyshyn O, Mamonov V, Phillips J, Guzman-Becerra N, Grigorian A, Ewenstein B, Wong WY. Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors. Haemophilia. 2014 Jan; 20(1):65-72. PMID: 23910578.
    Citations: 30     Fields:    Translation:HumansCTClinical Trials
  23. Mannucci PM, Kempton C, Millar C, Romond E, Shapiro A, Birschmann I, Ragni MV, Gill JC, Yee TT, Klamroth R, Wong WY, Chapman M, Engl W, Turecek PL, Suiter TM, Ewenstein BM. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood. 2013 Aug 01; 122(5):648-57. PMID: 23777763; PMCID: PMC3736194.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  24. Ehrlich HJ, Wong WY, Ewenstein BM, Dockal M, Turecek PL, Gringeri A, Chehadeh H, Löw-Baselli A, Scheiflinger F, Reininger AJ. Development of novel treatment options for patients with haemophilia. Hamostaseologie. 2013; 33 Suppl 1:S36-8. PMID: 24169902.
    Citations:    Fields:    Translation:Humans
  25. Wahl PM, Bohn RL, Terrell DR, George JN, Ewenstein B. Health care utilization of patients diagnosed with idiopathic thrombotic thrombocytopenic purpura in a commercially insured population in the United States. Transfusion. 2012 Jul; 52(7 Pt 2):1614-21. PMID: 22780943.
    Citations: 1     Fields:    Translation:Humans
  26. Auerswald G, Thompson AA, Recht M, Brown D, Liesner R, Guzmán-Becerra N, Dyck-Jones J, Ewenstein B, Abbuehl B. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012 Jun; 107(6):1072-82. PMID: 22476554; PMCID: PMC6292131.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  27. Björkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012 Jan 12; 119(2):612-8. PMID: 22042695.
    Citations: 57     Fields:    Translation:Humans
  28. Ewenstein BM, Reininger AJ. Re: low incidence of factor VIII inhibitors in PUPs during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study. Haemophilia. 2011 Sep; 17(5):e847-8. PMID: 21752157.
    Citations:    Fields:    Translation:Humans
  29. Losordo DW, Henry TD, Davidson C, Sup Lee J, Costa MA, Bass T, Mendelsohn F, Fortuin FD, Pepine CJ, Traverse JH, Amrani D, Ewenstein BM, Riedel N, Story K, Barker K, Povsic TJ, Harrington RA, Schatz RA. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011 Aug 05; 109(4):428-36. PMID: 21737787.
    Citations: 201     Fields:    Translation:HumansCellsCTClinical Trials
  30. Bonnet P, Gringeri A, Gomperts E, Leissinger CA, d'Oiron R, Teitel J, Young G, Franklin M, Ewenstein B, Berntorp E. Modeling costs and outcomes associated with a treatment algorithm for problem bleeding episodes in patients with severe hemophilia a and high-titer inhibitors. Am Health Drug Benefits. 2011 Jul; 4(4):219-31. PMID: 25126352.
    Citations: 1     
  31. Ewenstein B, Wong WY, Casey K, Alai M. FVIII administration in surgery. Haemophilia. 2011 Sep; 17(5):828-9. PMID: 21682821.
    Citations:    Fields:    Translation:Humans
  32. Klamroth R, Pollmann H, Hermans C, Faradji A, Yarlas AS, Epstein JD, Ewenstein BM. The relative burden of haemophilia A and the impact of target joint development on health-related quality of life: results from the ADVATE Post-Authorization Safety Surveillance (PASS) study. Haemophilia. 2011 May; 17(3):412-21. PMID: 21332888.
    Citations: 18     Fields:    Translation:Humans
  33. Fischer K, Collins P, Björkman S, Blanchette V, Oh M, Fritsch S, Schroth P, Spotts G, Ewenstein B. Trends in bleeding patterns during prophylaxis for severe haemophilia: observations from a series of prospective clinical trials. Haemophilia. 2011 May; 17(3):433-8. PMID: 21299740.
    Citations: 10     Fields:    Translation:Humans
  34. Oldenburg J, Goudemand J, Valentino L, Richards M, Luu H, Kriukov A, Gajek H, Spotts G, Ewenstein B. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice. Haemophilia. 2010 Nov; 16(6):866-77. PMID: 20579113.
    Citations: 8     Fields:    Translation:Humans
  35. Ewenstein BM, Wong WY, Schoppmann A. Bleeding reduction during secondary prophylaxis with bypassing agents in inhibitor patients. Thromb Res. 2011 Feb; 127(2):174-5. PMID: 20813397.
    Citations: 1     Fields:    Translation:Humans
  36. Björkman S, Blanchette VS, Fischer K, Oh M, Spotts G, Schroth P, Fritsch S, Patrone L, Ewenstein BM, Collins PW. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010 Apr; 8(4):730-6. PMID: 20398185.
    Citations: 29     Fields:    Translation:Humans
  37. Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010 Feb; 8(2):269-75. PMID: 19943875.
    Citations: 43     Fields:    Translation:Humans
  38. Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, Siekmann J, Schnecker K, Plaimauer B, Kaliwoda M, Purtscher M, Woehrer W, Mundt W, Muchitsch EM, Suiter T, Ewenstein B, Ehrlich HJ, Schwarz HP. Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie. 2009 Oct; 29 Suppl 1:S32-8. PMID: 19763356.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  39. Ewenstein BM, Wong WY, Schoppmann A. Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors. Haemophilia. 2010 Jan; 16(1):179-80. PMID: 19702885.
    Citations:    Fields:    Translation:Humans
  40. Konkle BA, Kessler C, Aledort L, Andersen J, Fogarty P, Kouides P, Quon D, Ragni M, Zakarija A, Ewenstein B. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia. 2009 Nov; 15(6):1197-209. PMID: 19686466.
    Citations: 8     Fields:    Translation:Humans
  41. Bonnet PO, Yoon BS, Wong WY, Boswell K, Ewenstein BM. Cost minimization analysis to compare activated prothrombin complex concentrate (APCC) and recombinant factor VIIa for haemophilia patients with inhibitors undergoing major orthopaedic surgeries. Haemophilia. 2009 Sep; 15(5):1083-9. PMID: 19456876.
    Citations: 4     Fields:    Translation:Humans
  42. Valentino LA, Carcao M, Mathew P, Leissinger CA, Berntorp E, Blanchette V, Escuriola-Ettingshausen C, Ewenstein B, Ewing N, Gringeri A, Hoots WK, Negrier C. The application of bypassing-agent prophylaxis in haemophilia A patients with inhibitors: a meeting report. Haemophilia. 2009 Jul; 15(4):959-65. PMID: 19320750.
    Citations: 2     Fields:    Translation:Humans
  43. Shapiro A, Gruppo R, Pabinger I, Collins PW, Hay CR, Schroth P, Casey K, Patrone L, Ehrlich H, Ewenstein BM. Integrated analysis of safety and efficacy of a plasma- and albumin-free recombinant factor VIII (rAHF-PFM) from six clinical studies in patients with hemophilia A. Expert Opin Biol Ther. 2009 Mar; 9(3):273-83. PMID: 19216617.
    Citations: 9     Fields:    Translation:Humans
  44. Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009 Mar; 7(3):413-20. PMID: 19143924.
    Citations: 84     Fields:    Translation:HumansCTClinical Trials
  45. Négrier C, Shapiro A, Berntorp E, Pabinger I, Tarantino M, Retzios A, Schroth P, Ewenstein B. Surgical evaluation of a recombinant factor VIII prepared using a plasma/albumin-free method: efficacy and safety of Advate in previously treated patients. Thromb Haemost. 2008 Aug; 100(2):217-23. PMID: 18690340.
    Citations: 17     Fields:    Translation:HumansCTClinical Trials
  46. Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM. Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost. 2008 Aug; 6(8):1319-26. PMID: 18503631.
    Citations: 32     Fields:    Translation:HumansPHPublic Health
  47. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol. 2008 Feb; 83(2):137-43. PMID: 17729241.
    Citations: 87     Fields:    Translation:Humans
  48. Teitel J, Berntorp E, Collins P, D'Oiron R, Ewenstein B, Gomperts E, Goudemand J, Gringeri A, Key N, Leissinger C, Monahan P, Young G. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia. 2007 May; 13(3):256-63. PMID: 17498074.
    Citations: 10     Fields:    Translation:Humans
  49. Berntorp E, Astermark J, Donfield SM, Nelson GW, Oldenburg J, Shapiro AD, Dimichele DM, Ewenstein BM, Gomperts ED, Winkler CA. Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods. Haemophilia. 2005 Jul; 11(4):427-9. PMID: 16011603.
    Citations: 1     Fields:    Translation:Humans
  50. Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia. 2005 May; 11(3):261-9. PMID: 15876272.
    Citations: 4     Fields:    Translation:Humans
  51. Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia. 2004 Sep; 10 Suppl 2:10-6. PMID: 15385041.
    Citations: 12     Fields:    Translation:Humans
  52. Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM. Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia. 2004 Sep; 10(5):428-37. PMID: 15357767.
    Citations: 43     Fields:    Translation:HumansCTClinical Trials
  53. Rodriguez-Merchan EC, Rocino A, Ewenstein B, Bartha L, Batorova A, Goudemand J, Gringeri A, Joao-Diniz M, Lopaciuk S, Negrier C, Quintana M, Tagariello G, Tjonnfjord GE, Villar VA, Vorlova Z. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia. 2004 Sep; 10 Suppl 2:50-2. PMID: 15385047.
    Citations: 12     Fields:    Translation:Humans
  54. Ewenstein BM, Valentino LA, Journeycake JM, Tarantino MD, Shapiro AD, Blanchette VS, Hoots WK, Buchanan GR, Manco-Johnson MJ, Rivard GE, Miller KL, Geraghty S, Maahs JA, Stuart R, Dunham T, Navickis RJ. Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia. 2004 Sep; 10(5):629-48. PMID: 15357790.
    Citations: 5     Fields:    Translation:HumansPHPublic Health
  55. Ewenstein BM, Gomperts ED, Pearson S, O'Banion ME. Inhibitor development in patients receiving recombinant factor VIII (Recombinate rAHF/Bioclate): a prospective pharmacovigilance study. Haemophilia. 2004 Sep; 10(5):491-8. PMID: 15357776.
    Citations: 5     Fields:    Translation:Humans
  56. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in haemophilia. Haemophilia. 2004 Mar; 10(2):134-46. PMID: 14962202.
    Citations: 11     Fields:    Translation:Humans
  57. Thompson AR, Gill JC, Ewenstein BM, Mueller-Velten G, Schwartz BA. Successful treatment for patients with von Willebrand disease undergoing urgent surgery using factor VIII/VWF concentrate (Humate-P). Haemophilia. 2004 Jan; 10(1):42-51. PMID: 14962219.
    Citations: 12     Fields:    Translation:HumansCTClinical Trials
  58. Bohn RL, Aledort LM, Putnam KG, Ewenstein BM, Mogun H, Avorn J. The economic impact of factor VIII inhibitors in patients with haemophilia. Haemophilia. 2004 Jan; 10(1):63-8. PMID: 14962222.
    Citations: 13     Fields:    Translation:Humans
  59. Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED. Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK. Semin Hematol. 2004 Jan; 41(1 Suppl 2):1-16; discussion 16-8. PMID: 15071785.
    Citations: 7     Fields:    Translation:HumansAnimals
  60. Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia. 2003 Nov; 9(6):688-95. PMID: 14750934.
    Citations: 14     Fields:    Translation:HumansCTClinical Trials
  61. Schwarz HP, Ewenstein B, Turecek PL. The 1st International Standard for von Willebrand Factor concentrate: more to come? Thromb Haemost. 2002 Sep; 88(3):376-7. PMID: 12353062.
    Citations:    Fields:    Translation:HumansCells
  62. Ewenstein BM, Joist JH, Shapiro AD, Hofstra TC, Leissinger CA, Seremetis SV, Broder M, Mueller-Velten G, Schwartz BA. Pharmacokinetic analysis of plasma-derived and recombinant F IX concentrates in previously treated patients with moderate or severe hemophilia B. Transfusion. 2002 Feb; 42(2):190-7. PMID: 11896334.
    Citations: 17     Fields:    Translation:Humans
  63. Mannucci PM, Chediak J, Hanna W, Byrnes J, Ledford M, Ewenstein BM, Retzios AD, Kapelan BA, Schwartz RS, Kessler C. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood. 2002 Jan 15; 99(2):450-6. PMID: 11781224.
    Citations: 29     Fields:    Translation:HumansCTClinical Trials
  64. Ewenstein BM, Avorn J, Putnam KG, Bohn RL. Porcine factor VIII: pharmacoeconomics of inhibitor therapy. Haemophilia. 2002 Jan; 8 Suppl 1:13-6; discussion 28-32. PMID: 11882077.
    Citations: 2     Fields:    Translation:HumansAnimals
  65. Datta YH, Ewenstein BM. Regulated secretion in endothelial cells: biology and clinical implications. Thromb Haemost. 2001 Nov; 86(5):1148-55. PMID: 11816699.
    Citations: 11     Fields:    Translation:HumansAnimalsCells
  66. Ewenstein BM. Continuous infusion of recombinant factor VIIa: continue or not? Thromb Haemost. 2001 Oct; 86(4):942-4. PMID: 11686349.
    Citations: 3     Fields:    Translation:HumansCells
  67. Cohen AJ, Kessler CM, Ewenstein BM. Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America. Haemophilia. 2001 May; 7(3):235-41. PMID: 11380626.
    Citations: 1     Fields:    Translation:Humans
  68. Soucie JM, Richardson LC, Evatt BL, Linden JV, Ewenstein BM, Stein SF, Leissinger C, Manco-Johnson M, Sexauer CL. Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion. 2001 Mar; 41(3):338-43. PMID: 11274587.
    Citations: 14     Fields:    Translation:Humans
  69. Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia. 2001 Jan; 7 Suppl 1:10-5. PMID: 11240613.
    Citations: 4     Fields:    Translation:Humans
  70. Ewenstein BM, Hoots WK, Lusher JM, DiMichele D, White GC, Adelman B, Nadeau K. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica. 2000 Oct; 85(10 Suppl):35-9. PMID: 11187868.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  71. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood. 2000 Sep 01; 96(5):1698-702. PMID: 10961866.
    Citations: 20     Fields:    Translation:Humans
  72. Datta YH, Youssoufian H, Marks PW, Ewenstein BM. Targeting of a heterologous protein to a regulated secretion pathway in cultured endothelial cells. Blood. 1999 Oct 15; 94(8):2696-703. PMID: 10515873.
    Citations: 4     Fields:    Translation:HumansCells
  73. Barabino GA, Liu XD, Ewenstein BM, Kaul DK. Anionic polysaccharides inhibit adhesion of sickle erythrocytes to the vascular endothelium and result in improved hemodynamic behavior. Blood. 1999 Feb 15; 93(4):1422-9. PMID: 9949187.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  74. Brodie SB, Keller MJ, Ewenstein BM, Sax PE. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients. AIDS. 1998 Dec 24; 12(18):2433-7. PMID: 9875581.
    Citations: 9     Fields:    Translation:Humans
  75. Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998 Dec; 80(6):912-8. PMID: 9869160.
    Citations: 44     Fields:    Translation:HumansCTClinical Trials
  76. Dharnidharka VR, Takemoto C, Ewenstein BM, Rosen S, Harris HW. Membranous glomerulonephritis and nephrosis post factor IX infusions in hemophilia B. Pediatr Nephrol. 1998 Oct; 12(8):654-7. PMID: 9811389.
    Citations: 4     Fields:    Translation:Humans
  77. Dioun AF, Ewenstein BM, Geha RS, Schneider LC. IgE-mediated allergy and desensitization to factor IX in hemophilia B. J Allergy Clin Immunol. 1998 Jul; 102(1):113-7. PMID: 9679854.
    Citations: 10     Fields:    Translation:Humans
  78. Anrather D, Millan MT, Palmetshofer A, Robson SC, Geczy C, Ritchie AJ, Bach FH, Ewenstein BM. Thrombin activates nuclear factor-kappaB and potentiates endothelial cell activation by TNF. J Immunol. 1997 Dec 01; 159(11):5620-8. PMID: 9548505.
    Citations: 16     Fields:    Translation:HumansAnimalsCells
  79. Ewenstein BM. Antithrombotic agents and thromboembolic disease. N Engl J Med. 1997 Nov 06; 337(19):1383-4. PMID: 9358134.
    Citations: 2     Fields:    Translation:Humans
  80. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, Miller RT, Pasi J, Rivard GE, Sommer SS, Katz J, Bergmann F, Ljung R, Petrini P, Lusher JM. Factor IX inhibitors and anaphylaxis in hemophilia B. Haemophilia. 1997 Jul; 3(3):231-2. PMID: 27214816.
    Citations:    Fields:    
  81. Barabino GA, Wise RJ, Woodbury VA, Zhang B, Bridges KA, Hebbel RP, Lawler J, Ewenstein BM. Inhibition of sickle erythrocyte adhesion to immobilized thrombospondin by von Willebrand factor under dynamic flow conditions. Blood. 1997 Apr 01; 89(7):2560-7. PMID: 9116303.
    Citations: 10     Fields:    Translation:HumansCells
  82. Gorlin JB, Ewenstein BM. Recombinant factor VIII: are we really getting more for less? J Pediatr. 1997 Apr; 130(4):507-9. PMID: 9108841.
    Citations:    Fields:    Translation:Humans
  83. Ewenstein BM, Takemoto C, Warrier I, Lusher J, Saidi P, Eisele J, Ettinger LJ, DiMichele D. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood. 1997 Feb 01; 89(3):1115-6. PMID: 9028348.
    Citations: 20     Fields:    Translation:Humans
  84. Ewenstein BM. Von Willebrand's disease. Annu Rev Med. 1997; 48:525-42. PMID: 9046981.
    Citations: 5     Fields:    Translation:Humans
  85. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, DiMichele D, Miller RT, Pasi J, Rivard GE, Sommer SS, Katz J, Bergmann F, Ljung R, Petrini P, Lusher JM. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol. 1997 Jan-Feb; 19(1):23-7. PMID: 9065715.
    Citations: 26     Fields:    Translation:Humans
  86. Bridges KR, Barabino GD, Brugnara C, Cho MR, Christoph GW, Dover G, Ewenstein BM, Golan DE, Guttmann CR, Hofrichter J, Mulkern RV, Zhang B, Eaton WA. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood. 1996 Dec 15; 88(12):4701-10. PMID: 8977264.
    Citations: 43     Fields:    Translation:HumansCells
  87. Ballen KK, Ritchie AJ, Murphy C, Handin RI, Ewenstein BM. Expression and activation of protein kinase C isoforms in a human megakaryocytic cell line. Exp Hematol. 1996 Nov; 24(13):1501-8. PMID: 8950233.
    Citations: 3     Fields:    Translation:HumansCells
  88. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am Heart J. 1996 Oct; 132(4):850-5. PMID: 8831376.
    Citations: 16     Fields:    Translation:Humans
  89. Warrier I, Ewenstein BM, Koerper MA, Shapiro A, Key N, Dimichele D, Miller RT, Pasi J, Rivard GE, Sommer SS, Bergmann F, Lusher JM. Factor IX inhibitors and anaphylaxis in haemophilia B. Haemophilia. 1996 Oct; 2(4):259-60. PMID: 27214369.
    Citations: 2     Fields:    
  90. Ewenstein BM. The pathophysiology of bleeding disorders presenting as abnormal uterine bleeding. Am J Obstet Gynecol. 1996 Sep; 175(3 Pt 2):770-7. PMID: 8828560.
    Citations: 3     Fields:    Translation:Humans
  91. Ragni MV, Belle SH, Jaffe R, Locker J, Duerstein SL, Bass DC, Addiego JE, Aledort LM, Barron LE, Brettler DB, Buchanan GR, Gill JC, Ewenstein BM, Green D, Hilgartner MW, Hoots WK, Kisker CT, Lovrien EW, Rutherford CJ, Sanders NL, Smith KJ, Stabler SP, Swindells S, White GC, Kingsley LA. AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Sep; 13(1):78-86. PMID: 8797689.
    Citations: 2     Fields:    Translation:Humans
  92. Hirsch DR, Mikkola KM, Marks PW, Fox EA, Dorfman DM, Ewenstein BM, Goldhaber SZ. Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: prevalence of factor V Leiden. Am Heart J. 1996 Jun; 131(6):1145-8. PMID: 8644593.
    Citations: 5     Fields:    Translation:HumansCells
  93. Datta YH, Romano M, Jacobson BC, Golan DE, Serhan CN, Ewenstein BM. Peptido-leukotrienes are potent agonists of von Willebrand factor secretion and P-selectin surface expression in human umbilical vein endothelial cells. Circulation. 1995 Dec 01; 92(11):3304-11. PMID: 7586318.
    Citations: 20     Fields:    Translation:HumansCells
  94. Windsor S, Lyng A, Taylor SA, Ewenstein BM, Neufeld EJ, Lillicrap D. Severe haemophilia A in a female resulting from two de novo factor VIII mutations. Br J Haematol. 1995 Aug; 90(4):906-9. PMID: 7669670.
    Citations: 6     Fields:    Translation:Humans
  95. Birch KA, Ewenstein BM, Golan DE, Pober JS. Prolonged peak elevations in cytoplasmic free calcium ions, derived from intracellular stores, correlate with the extent of thrombin-stimulated exocytosis in single human umbilical vein endothelial cells. J Cell Physiol. 1994 Sep; 160(3):545-54. PMID: 7521337.
    Citations: 13     Fields:    Translation:HumansCells
  96. Kondo NI, Maddi R, Ewenstein BM, Goldhaber SZ. Anticoagulation and hemostasis in cardiac surgical patients. J Card Surg. 1994 Jul; 9(4):443-61. PMID: 7949674.
    Citations:    Fields:    Translation:Humans
  97. Wise RJ, Ewenstein BM, Gorlin J, Narins SC, Jesson M, Handin RI. Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation. Hum Genet. 1993 May; 91(4):367-72. PMID: 8500791.
    Citations:    Fields:    Translation:HumansCells
  98. Birch KA, Pober JS, Zavoico GB, Means AR, Ewenstein BM. Calcium/calmodulin transduces thrombin-stimulated secretion: studies in intact and minimally permeabilized human umbilical vein endothelial cells. J Cell Biol. 1992 Sep; 118(6):1501-10. PMID: 1522120; PMCID: PMC2289613.
    Citations: 19     Fields:    Translation:HumansCells
  99. Jacobson BC, Pober JS, Fenton JW, Ewenstein BM. Thrombin and histamine rapidly stimulate the phosphorylation of the myristoylated alanine-rich C-kinase substrate in human umbilical vein endothelial cells: evidence for distinct patterns of protein kinase activation. J Cell Physiol. 1992 Jul; 152(1):166-76. PMID: 1320036.
    Citations: 4     Fields:    Translation:HumansCells
  100. Ritchie AJ, Johnson DR, Ewenstein BM, Pober JS. Tumor necrosis factor induction of endothelial cell surface antigens is independent of protein kinase C activation or inactivation. Studies with phorbol myristate acetate and staurosporine. J Immunol. 1991 May 01; 146(9):3056-62. PMID: 1707932.
    Citations: 16     Fields:    Translation:HumansCells
  101. Ewenstein BM, Jacobson BC, Birch KA. Regulated secretion in vascular endothelium. Adv Exp Med Biol. 1991; 314:141-57. PMID: 1818484.
    Citations:    Fields:    Translation:HumansAnimalsCells
  102. Ewenstein BM, Inbal A, Pober JS, Handin RI. Molecular studies of von Willebrand disease: reduced von Willebrand factor biosynthesis, storage, and release in endothelial cells derived from patients with type I von Willebrand disease. Blood. 1990 Apr 01; 75(7):1466-72. PMID: 2317558.
    Citations: 6     Fields:    Translation:HumansCells
  103. Zavoico GB, Ewenstein BM, Schafer AI, Pober JS. IL-1 and related cytokines enhance thrombin-stimulated PGI2 production in cultured endothelial cells without affecting thrombin-stimulated von Willebrand factor secretion or platelet-activating factor biosynthesis. J Immunol. 1989 Jun 01; 142(11):3993-9. PMID: 2497185.
    Citations: 13     Fields:    Translation:HumansCells
  104. Faller DV, Kourembanas S, Ginsberg D, Hannan R, Collins T, Ewenstein BM, Pober JS, Tantravahi R. Immortalization of human endothelial cells by murine sarcoma viruses, without morphologic transformation. J Cell Physiol. 1988 Jan; 134(1):47-56. PMID: 2826502.
    Citations: 9     Fields:    Translation:HumansCells
  105. Ewenstein BM, Warhol MJ, Handin RI, Pober JS. Composition of the von Willebrand factor storage organelle (Weibel-Palade body) isolated from cultured human umbilical vein endothelial cells. J Cell Biol. 1987 May; 104(5):1423-33. PMID: 3494734; PMCID: PMC2114468.
    Citations: 43     Fields:    Translation:HumansCells
  106. Bonthron DT, Handin RI, Kaufman RJ, Wasley LC, Orr EC, Mitsock LM, Ewenstein B, Loscalzo J, Ginsburg D, Orkin SH. Structure of pre-pro-von Willebrand factor and its expression in heterologous cells. Nature. 1986 Nov 20-26; 324(6094):270-3. PMID: 3491324.
    Citations: 49     Fields:    Translation:AnimalsCells
  107. Antin JH, Smith BR, Ewenstein BM, Arceci RJ, Lipton JM, Page PL, Rappeport JM. HTLV-III infection after bone marrow transplantation. Blood. 1986 Jan; 67(1):160-3. PMID: 3000475.
    Citations: 1     Fields:    Translation:HumansCells
  108. Pease LR, Ewenstein BM, McGovern D, Melvold RW, Nisizawa T, Nathenson SG. Biochemical studies on the H-2K mutant B6.C-H-2bm10. Immunogenetics. 1983; 17(1):7-17. PMID: 6826210.
    Citations: 3     Fields:    Translation:AnimalsCells
  109. Coligan JE, Gates FT, Kindt TJ, Ewenstein BM, Martinko JM, Uehara H, Nathenson SG. Primary structure of murine H-2Kb and beta 2-microglobulin. Transplant Proc. 1981 Dec; 13(4):1792-6. PMID: 6173945.
    Citations:    Fields:    Translation:HumansAnimals
  110. Nathenson SG, Uehara H, Ewenstein BM, Kindt TJ, Coligan JE. Primary structural: analysis of the transplantation antigens of the murine H-2 major histocompatibility complex. Annu Rev Biochem. 1981; 50:1025-52. PMID: 7023355.
    Citations: 84     Fields:    Translation:AnimalsCells
  111. Nisizawa T, Ewenstein BM, Uehara H, McGovern D, Nathenson SG. Biochemical studies on the H-2K antigens of the MHC mutant bml. Immunogenetics. 1981; 12(1-2):33-44. PMID: 6782017.
    Citations: 9     Fields:    Translation:AnimalsCells
  112. Uehara H, Ewenstein BM, Martinko JM, Nathenson SG, Kindt TJ, Coligan JE. Primary structure of murine major histocompatibility alloantigens: amino acid sequence of the cyanogen bromide fragment Ia (positions 139-228) from the H-2Kb molecule. Biochemistry. 1980 Dec 23; 19(26):6182-8. PMID: 7470457.
    Citations: 6     Fields:    Translation:AnimalsCells
  113. Martinko JM, Uehara H, Ewenstein BM, Kindt TJ, Coligan JE, Nathenson SG. Primary structure of murine major histocompatibility complex alloantigens: completion of the sequence of the amino-terminal 284 residues of H-2Kb. Biochemistry. 1980 Dec 23; 19(26):6188-93. PMID: 7470458.
    Citations: 5     Fields:    Translation:AnimalsCells
  114. Uehara H, Ewenstein BM, Martinko JM, Nathenson SG, Coligan JE, Kindt TJ. Primary structure of murine major histocompatibility complex alloantigens: amino acid sequence of the amino-terminal one hundred and seventy-three residues of the H-2Kb glycoprotein. Biochemistry. 1980 Jan 22; 19(2):306-15. PMID: 6986168.
    Citations: 16     Fields:    Translation:AnimalsCells
  115. Ewenstein BM, Uehara H, Nisizawa T, Melvold RW, Kohn HI, Nathenson SG. Biochemical studies on the H-2K antigens of the MHC mutants bm3 and bm11. Immunogenetics. 1980; 11(4):383-95. PMID: 7429601.
    Citations: 12     Fields:    Translation:AnimalsCells
  116. Coligan JE, Kindt TJ, Ewenstein BM, Uehara H, Martinko JM, Nathenson SG. Further structural analysis of the murine H-2Kb glycoprotein using radiochemical methodology. Mol Immunol. 1979 Jan; 16(1):3-8. PMID: 447367.
    Citations: 7     Fields:    Translation:HumansAnimalsCells
  117. Coligan JE, Kindt TJ, Ewenstein BM, Uehara H, Nisizawa T, Nathenson SG. Primary structure of murine major histocompatibility complex alloantigens: amino acid sequence studies of the cyanogen bromide fragments of the H-2Kb glycoprotein. Proc Natl Acad Sci U S A. 1978 Jul; 75(7):3390-4. PMID: 277939; PMCID: PMC392782.
    Citations: 16     Fields:    Translation:AnimalsCells
  118. Ewenstein BM, Nisizawa T, Uehara H, Nathenson SG, Coligan JE, Kindt TJ. Primary structure of murine major histocompatibility complex alloantigens: isolation, biochemical characterization, and preliminary alignment of CNBr fragments from the H-2Ib glycoprotein. Proc Natl Acad Sci U S A. 1978 Jun; 75(6):2909-13. PMID: 275861; PMCID: PMC392675.
    Citations: 14     Fields:    Translation:AnimalsCells
  119. Nathenson SG, Ewenstein BM, Brown JL, Nisizawa T, Uehara H, Sears DW. The structural-genetic relationships of the H-2K and H-2D products of the mouse major histocompatibility complex. Birth Defects Orig Artic Ser. 1978; 14(2):217-33. PMID: 76485.
    Citations: 1     Fields:    Translation:Animals
  120. Nathenson SG, Brown JL, Ewenstein BM, Nisizawa T, Sears DW, Freed JH. Structural differences between parent and variant H-2K glycoproteins from mouse strains carrying H-2 gene mutations. Cold Spring Harb Symp Quant Biol. 1977; 41 Pt 1:343-9. PMID: 268255.
    Citations: 6     Fields:    Translation:AnimalsCells
  121. Ewenstein BM, Freed JH, Mole LE, Nathenson SG. Localization of the papain cleavage site of H-2 glycoproteins. Proc Natl Acad Sci U S A. 1976 Mar; 73(3):915-8. PMID: 1062805; PMCID: PMC336030.
    Citations: 17     Fields:    Translation:AnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Ewenstein's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (430)
Explore
_
Co-Authors (22)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.